Kim N. Chi

May 21, 2024 | targetedonc.com | Kim N. Chi

Kim N. Chi, MD, FRCPC, medical oncologist, vice president, chief medical officer, British Columbia Cancer, professor, Division of Medical Oncology, University of British Columbia, discusses how the findings from the phase 3 MAGNITUDE trial (NCT03748641) translate into everyday practice. The MAGNITUDE trial is evaluating the combination of niraparib, abiraterone acetate, and prednisone (AAP) for the treatment of patients with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC).

Apr 4, 2024 | targetedonc.com | Kim N. Chi

Kim N. Chi, MD, FRCPC, medical oncologist, vice president, chief medical officer, British Columbia Cancer, professor, Division of Medical Oncology, University of British Columbia, discusses the significance of the phase 3 MAGNITUDE trial (NCT03748641), including its evaluation on patient-reported outcomes, in patients with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC).

Oct 3, 2023 | cuaj.ca | Ricardo Rendon |Bobby Shayegan |Kim N. Chi

Rendon, R. A., Selvarajah, S. ., Wyatt, A. W., Kolinsky, M. ., Schrader, K. A. ., Fleshner, N. E. ., Kinnaird, A. ., Merrimen, J. ., Niazi, T. ., Saad, F. ., Shayegan, B. ., Wood, L. ., & Chi, K. N. (2023). 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer. Canadian Urological Association Journal, 17(10), 314–25. https://doi.org/10.5489/cuaj.8588